Gara Jalqabaatti › Limfoomaa Selii-T Qoqaa
Qorannoo klinikaalii Limfoomaa Selii-T Qoqaa Ameerikaa Keessatti hirmaatuu
Qorannoo 29 Limfoomaa Selii-T Qoqaa f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- New York City, NYQorannoo 9
- Baldwin Park, CAQorannoo 8
- Boston, MAQorannoo 5
- Houston, TXQorannoo 5
- New Haven, CTQorannoo 4
- Tampa, FLQorannoo 3
- Durham, NCQorannoo 3
- Ann Arbor, MIQorannoo 3
- Columbus, OHQorannoo 3
- Rochester, MNQorannoo 3
- Chicago, ILQorannoo 3
- Scottsdale, AZQorannoo 3
Naannoon
- ArizonaQorannoo 3
- CaliforniaQorannoo 8
- ConnecticutQorannoo 4
- FloridaQorannoo 3
- IllinoisQorannoo 3
- MassachusettsQorannoo 5
- MichiganQorannoo 3
- MinnesotaQorannoo 3
- New YorkQorannoo 10
- North CarolinaQorannoo 3
- OhioQorannoo 4
- PennsylvaniaQorannoo 4
- TexasQorannoo 5
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT04234048A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07192471Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT01087333A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07195916A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06854653Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Ful-2026 · NCT04930653Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 31-Ado-2026 · NCT03011814A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Ado-2026 · NCT04045470A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 13-Ado-2026 · NCT06698822Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ado-2026 · NCT06860880Registry of Older Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 65 fi ol · Saalaa hunda · Haaromfame 29-Wax-2026 · NCT01137825Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Wax-2026 · NCT05313243A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Wax-2026 · NCT03017820A Registry for People With T-cell Lymphoma
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 20-Cam-2026 · NCT05978141Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Cam-2026 · NCT05956041Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 89 · Saalaa hunda · Haaromfame 01-Cam-2026 · NCT03932279Photopheresis in Early-stage Mycosis Fungoides
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Elb-2026 · NCT05680558Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 15-Elb-2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Elb-2026 · NCT05996185Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT07047885Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Gur-2026 · NCT04848064A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Gur-2026 · NCT05296304Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ama-2026 · NCT04670874Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Mud-2025 · NCT00177268Amping up With PemJAK
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 95 · Saalaa hunda · Haaromfame 16-Mud-2025 · NCT07283822Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.